Citadel Advisors
COGT icon

Citadel Advisors’s Cogent Biosciences COGT Stock Holding History

Citadel Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.72M Buy
147,800
+46,200
+45% +$1.62M ﹤0.01% 4493
2026
Q1 		$3.91M Buy
101,600
+28,500
+39% +$1.05M ﹤0.01% 4757
2025
Q4 		$2.6M Buy
73,100
+61,000
+504% +$1.71M ﹤0.01% 5441
2025
Q3 		$174K Sell
12,100
-38,300
-76% -$454K ﹤0.01% 11404
2025
Q2 		$362K Buy
50,400
+42,000
+500% +$233K ﹤0.01% 9376
2025
Q1 		$50.3K Sell
8,400
-31,900
-79% -$250K ﹤0.01% 12310
2024
Q4 		$314K Buy
40,300
+2,100
+5% +$20.9K ﹤0.01% 9561
2024
Q3 		$413K Buy
38,200
+1,600
+4% +$15.6K ﹤0.01% 8673
2024
Q2 		$309K Buy
36,600
+8,800
+32% +$66.7K ﹤0.01% 9081
2024
Q1 		$187K Sell
27,800
-18,700
-40% -$116K ﹤0.01% 10428
2023
Q4 		$273K Buy
46,500
+26,600
+134% +$204K ﹤0.01% 9339
2023
Q3 		$194K Buy
19,900
+4,000
+25% +$47.4K ﹤0.01% 9969
2023
Q2 		$188K Buy
15,900
+2,900
+22% +$33.3K ﹤0.01% 9989
2023
Q1 		$140K Sell
13,000
-23,900
-65% -$306K ﹤0.01% 10750
2022
Q4 		$427K Sell
36,900
-11,100
-23% -$138K ﹤0.01% 8573
2022
Q3 		$716K Sell
48,000
-10,700
-18% -$147K ﹤0.01% 7706
2022
Q2 		$529K Buy
+58,700
New +$401K ﹤0.01% 8520

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's COGT Position: Q2 2026 in Review

Citadel Advisors reduced its Cogent Biosciences (COGT) stake by 50% in Q2 2026, selling an estimated $30.3M and leaving 849,694 shares worth $32.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1992.

Citadel Advisors first reported a position in COGT in Q1 2018 and has held it in 27 quarters since. The position peaked at $66M in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Citadel Advisors held 849,694 shares of Cogent Biosciences worth $32.9M as of Q2 2026.
  • Citadel Advisors sold 865,233 Cogent Biosciences shares in Q2 2026, an estimated $30.3M.
  • Cogent Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1992 holding.
  • Citadel Advisors first reported a position in Cogent Biosciences in Q1 2018 and has held it in 27 quarters since.
  • Citadel Advisors's Cogent Biosciences position peaked at $66M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.